Harvard Catalyst has transcended the boundaries long imposed by the historical, corporate, and cultural independence of Harvard and its 17 affiliated academic healthcare centers (AHCs) to bring cross-disciplinary investigators together to collaborate and form teams to conduct clinical and translational (CT) research. Today education, resources and services are jointly planned, executed, broadly shared, and evaluated with the common goal of improving the quality, speed, safety, efficiency and cost across the entire spectrum of CT research. Ongoing CTSA recognition coupled with the opportunity to be a significant participant in the Consortium will enable Harvard Catalyst to implement its vision and strategic plan. First, we will convene investigators from our 11 schools and 17 AHCs to identify and prioritize the most important opportunities in CT research. We will help them to connect with one another to form cross-disciplinary teams and then provide them with the opportunities, incentives, and access to outstanding education and resources in an environment that values innovation, collaboration, and team science. Second, we will work with our schools and AHCs to build and grow an environment where discoveries are rapidly and efficiently translated to improve human health. Simply stated, Harvard Catalyst strives to be a Convener, Connector and Catalyst to hasten and improve the quality CT research. To this end, we have structured our academic home to create an integrated pathway of education, training, and career development and to provide a full portfolio of innovative resources and services to address identified gaps and investigator needs. Within five years, our achievements will include: 1) a continuous, sustainable, robust pipeline of future team leaders across all CT domains;2) implementation of SHRINE-CT coupled with resolution of regulatory hurdles to allow nvestigators to rapidly identify, contact, and accrue specific patients to clinical trials across institutions and throughout the Consortium;3) establishment of a team of experts who will reduce the barriers to engagement and entry to human experimentation thereby growing and diversifying the community of investigators who conduct CT research;4) infrastructure to provide all CT investigators access to the resources they need to conduct human clinical studies wherever their work is best done;and 5) systematic investigation of innovative methodologies to incentivize, form and nurture teams to create new preventions, biomarkers, and therapeutics. These achievements will continue the transformation of CT research at Harvard with the goal of catalyzing a """"""""One Harvard"""""""" community and culture committed to improving health.

Public Health Relevance

The Harvard Clinical and Translational Science Center supports an academic home that creates an integrated research and training environment across Harvard Medical School and its partner institutions in order to improve human health. It provides and/or creates access to resources and services to support all steps of clinical research across the full spectrum of clinical and translational research, and facilitates the training and career development of the translational research workforce.

Agency
National Institute of Health (NIH)
Institute
National Center for Advancing Translational Sciences (NCATS)
Type
Mentored Career Development Award (KL2)
Project #
1KL2TR001100-01
Application #
8721083
Study Section
Special Emphasis Panel (ZAI1-PTM-C (S1))
Program Officer
Talbot, Bernard
Project Start
2013-09-26
Project End
2018-04-30
Budget Start
2013-09-26
Budget End
2014-04-30
Support Year
1
Fiscal Year
2013
Total Cost
$1,131,170
Indirect Cost
Name
Harvard University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
047006379
City
Boston
State
MA
Country
United States
Zip Code
02115
Moskowitz, Ari; Ross, Catherine E; Andersen, Lars W et al. (2018) Trends Over Time in Drug Administration During Adult In-Hospital Cardiac Arrest. Crit Care Med :
Emdin, Connor A; Khera, Amit V; Chaffin, Mark et al. (2018) Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nat Commun 9:1613
Choi, Kyungyong; Ryu, Hyunryul; Siddle, Katherine J et al. (2018) Negative Selection by Spiral Inertial Microfluidics Improves Viral Recovery and Sequencing from Blood. Anal Chem 90:4657-4662
Ogino, Shuji; Nowak, Jonathan A; Hamada, Tsuyoshi et al. (2018) Integrative analysis of exogenous, endogenous, tumour and immune factors for precision medicine. Gut 67:1168-1180
Hamada, Tsuyoshi; Soong, Thing Rinda; Masugi, Yohei et al. (2018) TIME (Tumor Immunity in the MicroEnvironment) classification based on tumor CD274 (PD-L1) expression status and tumor-infiltrating lymphocytes in colorectal carcinomas. Oncoimmunology 7:e1442999
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749
Liu, Li; Tabung, Fred K; Zhang, Xuehong et al. (2018) Diets That Promote Colon Inflammation Associate With Risk of Colorectal Carcinomas That Contain Fusobacterium nucleatum. Clin Gastroenterol Hepatol 16:1622-1631.e3
Foldyna, Borek; Fourman, Lindsay T; Lu, Michael T et al. (2018) Sex Differences in Subclinical Coronary Atherosclerotic Plaque Among Individuals With HIV on Antiretroviral Therapy. J Acquir Immune Defic Syndr 78:421-428
Salami, Joseph A; Warraich, Haider J; Valero-Elizondo, Javier et al. (2018) National Trends in Nonstatin Use and Expenditures Among the US Adult Population From 2002 to 2013: Insights From Medical Expenditure Panel Survey. J Am Heart Assoc 7:
Ngonzi, Joseph; Bebell, Lisa M; Fajardo, Yarine et al. (2018) Incidence of postpartum infection, outcomes and associated risk factors at Mbarara regional referral hospital in Uganda. BMC Pregnancy Childbirth 18:270

Showing the most recent 10 out of 206 publications